Columnist Desiree Lama has always known she wanted to help people; now she is achieving that goal through MS advocacy.
BNT23001, a sublingual formulation of cladribine, will be tested in a pilot clinical trial in 2025 comparing it to MS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback